Curant Health President and CEO, Patrick Dunham, and Director of Clinical Services, Vickie Andros, discuss our C the Cure program hepatitis c cure rate for co-infected HIV and hepatitis C patients.
Access assistance and MTM protocols key to successfully curing hepatitis C in co-infected patients.
For a cohort of hepatitis C and HIV co-infected patients, Curant Health reports that its C The Cure program produces sustained virological response (SVR12) in 89.7% of program patients at 12 weeks post treatment. SVR12 is the medical term associated with successful hepatitis C treatment outcomes. Patients with SVR12 have undetectable levels of hepatitis C viral load in their blood and are considered “cured,” no longer requiring treatment for the disease.
The referenced patient cohort included co-infected patients with hepatitis C who were both treatment naïve and treatment experienced, predominantly with genotype 1 and who most commonly followed treatment regimens that included Harvoni or Sovaldi.
This data is only the second real world data set known for this patient profile and treatment regimens.
To read the full press release, click here.
To learn more about Curant Health, contact Kristin Lindsey, Marketing Director, at klindsey@curanthealth.com.